Fennec Pharmaceuticals Inc. Stock

$8.71

1.02%

Nasdaq, Jul 07, 03:42 pm CET

ISIN

CA31447P1009

Symbol

FENC

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Fennec Pharmaceuticals Inc. Stock price

$8.80

+0.58 7.06% 5Y

Nasdaq, Closing price Thu, Jul 03 2025

+0.26 3.04%

ISIN

CA31447P1009

Symbol

FENC

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$243.0m

Enterprise Value

$238.6m

Net debt

positive

Cash

$22.7m

Shares outstanding

27.6m

Valuation (TTM | estimate)

P/E

negative | 58.3

P/S

7.9 | 5.1

EV/Sales

7.7 | 5.0

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

-13.1%

Return on Equity

7.4%

ROCE

-31.5%

ROIC

Debt/Equity

-3.1

Financials (TTM | estimate)

Revenue

$30.9m | $47.9m

EBITDA

- | $11.9m

EBIT

$-12.0m | $2.0m

Net Income

$-14.4m | $4.2m

Free Cash Flow

$-16.4m

Growth (TTM | estimate)

Revenue

-31.3% | 0.8%

EBITDA

- | -

EBIT

-292.2% | -

Net Income

-606.7% | 1,045.5%

Free Cash Flow

-159.6%

EPS

$-0.5

FCF per Share

$-0.6

Short interest

7.2%

Employees

Rev per Employee

$1.5m

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Get Started for Free Today

Fennec Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

10x Buy

91%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

Buy

91%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Fennec Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	31 31	31% 31% 100%
- Direct Costs	3.01 3.01	75% 75% 10%
Gross Profit	28 28	35% 35% 90%
- Selling and Administrative Expenses	39 39	7% 7% 128%
- Research and Development Expense	0.40 0.40	567% 567% 1%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-12 -12	292% 292% -39%
Net Profit	-14 -14	607% 607% -47%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Fennec Pharmaceuticals Inc. Stock News

Neutral

GlobeNewsWire

●

about one month ago

Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 25, 2025 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 3, 2025.

Neutral

Seeking Alpha

●

about 2 months ago

Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig Hallum Sudan Loganathan - Stevens Michael Okunewitch - Maxim Group Raghuram Selvaraju - H.C. Wainwright Operator Good morning,...

Neutral

GlobeNewsWire

●

about 2 months ago

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to di...

More Fennec Pharmaceuticals Inc. News

Company Profile

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Head office	Canada
CEO	Jeffrey Hackman
Employees	32
Founded	1996
Website	fennecpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now